Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xencor, Inc. - Common Stock
(NQ:
XNCR
)
24.80
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xencor, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
February 16, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
February 02, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
January 11, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022
From
Xencor, Inc.
Via
Business Wire
Xencor: Q3 Earnings Insights
November 08, 2021
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
December 12, 2021
From
Xencor, Inc.
Via
Business Wire
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal
November 27, 2021
In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to...
Via
Talk Markets
Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine
November 24, 2021
Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's...
Via
Benzinga
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma
November 22, 2021
Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a...
Via
Benzinga
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
November 21, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
November 19, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Novartis Dumps Another Bispecific Candidate From Xencor Deal
November 09, 2021
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...
Via
Benzinga
Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript
November 08, 2021
XNCR earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
November 08, 2021
From
Xencor, Inc.
Via
Business Wire
Preview: Xencor's Earnings
November 05, 2021
Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
November 04, 2021
From
Xencor, Inc.
Via
Business Wire
Earnings Scheduled For November 8, 2021
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
November 03, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at Upcoming Investor Conferences
November 02, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
November 01, 2021
From
Xencor, Inc.
Via
Business Wire
JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
October 04, 2021
Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global...
Via
Benzinga
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
October 04, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
October 01, 2021
From
Xencor, Inc.
Via
Business Wire
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 20, 2021
From
Xencor, Inc.
Via
Business Wire
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
August 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Return on Capital Employed Insights for Xencor
August 20, 2021
After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
August 20, 2021
On Friday morning, 155 companies achieved new lows for the year. Interesting Points: Marqeta (NASDAQ:MQ) was the largest firm on a market cap basis to set a new 52-...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.